Document Detail


The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-Medronate incorporation.
MedLine Citation:
PMID:  10226551     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hexakis-2-methoxyisobutylisonitrile (SestaMIBI) and 1,2-bis[bis(2-ethoxyethyl)phosphino]ethane (tetrofosmin) are 99mtechnetium compounds widely used in oncologic imaging. We investigated the uptake and release of SestaMIBI and tetrofosmin together with 99mTc-medronate in the MCF7 breast carcinoma cell line. All the tracers showed similar uptake kinetics, with a rapid increase in the first 30 minutes and a slower trend up to 120 minutes. Cell-associated activity was the same for SestaMIBI and tetrofosmin (4% of administered activity) and considerably lower for medronate (0.8%). For all tracers, almost all the accumulated activity was released within 1 hour. Furthermore, to verify an association between cell proliferation and tracer uptake, we performed growth-curve uptake experiments. Tetrofosmin uptake was lower in the logarithmic phase and higher in the plateau phase, whilst SestaMIBI showed the opposite trend. The differences between the tracers could be due to a relationship between proliferation and SestaMIBI uptake, or even to the influence of medium pH on membrane potential.
Authors:
S N Molteni; E Seregni; C Botti; A Martinetti; L Ferrari; F Crippa; E Bombardieri
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  19     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    1999 Jan-Feb
Date Detail:
Created Date:  1999-05-20     Completed Date:  1999-05-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  GREECE    
Other Details:
Languages:  eng     Pagination:  255-9     Citation Subset:  IM    
Affiliation:
Nuclear Medicine Division, Istituto Nazionale dei Tumori, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breast Neoplasms / metabolism*
Female
Humans
Organophosphorus Compounds / pharmacokinetics*
Organotechnetium Compounds / pharmacokinetics*
Technetium Tc 99m Medronate / pharmacokinetics*
Technetium Tc 99m Sestamibi / pharmacokinetics*
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Organophosphorus Compounds; 0/Organotechnetium Compounds; 0/technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; 109581-73-9/Technetium Tc 99m Sestamibi; 63347-66-0/Technetium Tc 99m Medronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reversal of methotrexate resistance in human squamous carcinoma cells by SQM1-liposome.
Next Document:  Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in...